

THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

Tracking SARS-CoV-2 mutations and variants through the COG-**UK-Mutation Explorer**

Citation for published version:

COVID-19 Genomics UK (COG-UK) Consortium, Wright, DW & Harvey, WT 2022, 'Tracking SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer', Virus Evolution, vol. 8, no. 1, veac023. https://doi.org/10.1093/ve/veac023

Digital Object Identifier (DOI):

10.1093/ve/veac023

Link:

Link to publication record in Edinburgh Research Explorer

Document Version: Publisher's PDF, also known as Version of record

Published In: Virus Evolution

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Resources

Tracking SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer

Derek W. Wright,¹ William T. Harvey,^{1,†} Joseph Hughes,^{1,‡} MacGregor Cox,² Thomas P Peacock,³ Rachel Colquhoun,^{4,§} Ben Jackson,^{4,*} Richard Orton,^{1,††} Morten Nielsen,^{5,‡‡} Nienyun Sharon Hsu,⁶ The COVID-19 Genomics UK (COG-UK) consortium,⁷ Ewan M. Harrison,^{2,8,9} Thushan I de Silva,⁶ Andrew Rambaut,^{4,§§} Sharon J. Peacock,^{2,**} David L. Robertson,^{1,*,†††} and Alessandro M. Carabelli^{2,*,‡‡‡}

¹MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Garscube Campus, 464 Bearsden Road, Glasgow G61 1QH, UK, ²Department of Medicine, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 0QQ, UK, ³Department of Infectious Disease, St Mary's Medical School, Imperial College London, Praed Street, London, Westminster W2 1NY, UK, ⁴Institute of Evolutionary Biology, University of Edinburgh, Charlotte Auerbach Road, Edinburgh EH9 3FL, UK, ⁵Department of Health Technology, Technical University of Denmark, Lyngby DK-2800, Denmark, ⁶The Florey Institute for Host-Pathogen Interactions and Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK, ⁷https://www.cogconsortium.uk, Full list of consortium names and affiliations are in Appendix 1, ⁸Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton CB10 1SA, UK and ⁹Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK

<sup>thttps://orcid.org/0000-0001-9529-1127
<sup>thttps://orcid.org/0000-0003-2556-2563
<sup>ghttps://orcid.org/0000-0002-5577-9897
"thttps://orcid.org/0000-0002-3389-4325
<sup>thttps://orcid.org/0000-0001-7885-4311
<sup>ghttps://orcid.org/0000-0002-1788-4311
"thttps://orcid.org/0000-0002-1718-2782
"thttps://orcid.org/0000-0002-1718-2782
"thttps://orcid.org/0000-0001-6338-0221</sup></sup></sup></sup></sup>

⁺⁺⁺https://orcid.org/0000-0003-3625-4021

*Corresponding authors: E-mail: david.l.robertson@glasgow.ac.uk; amc257@medsch.cam.ac.uk

Abstract

COG-UK Mutation Explorer (COG-UK-ME, https://sars2.cvr.gla.ac.uk/cog-uk/—last accessed date 16 March 2022) is a web resource that displays knowledge and analyses on SARS-CoV-2 virus genome mutations and variants circulating in the UK, with a focus on the observed amino acid replacements that have an antigenic role in the context of the human humoral and cellular immune response. This analysis is based on more than 2 million genome sequences (as of March 2022) for UK SARS-CoV-2 data held in the CLIMB-COVID centralised data environment. COG-UK-ME curates these data and displays analyses that are cross-referenced to experimental data collated from the primary literature. The aim is to track mutations of immunological importance that are accumulating in current variants of concern and variants of interest that could alter the neutralising activity of monoclonal antibodies (mAbs), convalescent sera, and vaccines. Changes in epitopes recognised by T cells, including those where reduced T cell binding has been demonstrated, are reported. Mutations that have been shown to confer SARS-CoV-2 resistance to antiviral drugs are also included. Using visualisation tools, COG-UK-ME also allows users to identify the emergence of variants carrying mutations that could decrease the neutralising activity of both mAbs present in therapeutic cocktails, e.g. Ronapreve. COG-UK-ME tracks changes in the frequency of combinations of mutations and brings together the curated literature on the impact of those mutations on various functional aspects of the virus and therapeutics. Given the unpredictable nature of SARS-CoV-2 as exemplified by yet another variant of concern, Omicron, continued surveillance of SARS-CoV-2 remains imperative to monitor virus evolution linked to the efficacy of therapeutics.

Key words: SARS-CoV-2; COVID-19; virus; spike; protein structure; antibody escape; antigenic variation; mutation; amino acid replacements; variants of concern; evasion; resistance; fitness; evolution.

1. Introduction

As of March 2022, SARS-CoV-2, the causative agent of COVID-19, has accounted for over 450 million infections and 6 million deaths worldwide (https://covid19.who.int/). SARS-CoV-2 was first identified at the end of 2019 in the city of Wuhan, China, and has since spread with unprecedented efficiency among humans (Hu et al. 2021). In contrast to other RNA viruses, the *Coronaviridae* family is characterised by relatively high-replication fidelity due to the

proofreading activity of their polymerases (Robson et al. 2020). Early analyses of SARS-CoV-2 genomes estimated an evolutionary rate of around 0.001 subs/site/year (two to three mutations per month) (Duchene et al. 2020); however, there is much deviation from this rate across the phylogeny with several outlier lineages, including variants of concern (VOCs), that have rapidly acquired several mutations at a much higher rate than this. The analysis of mutations from virus genome data is important for basic virology

[©] The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

(Houldcroft et al. 2017), to identify evolutionary signals associated with mutations prior to experimental and real-world data on clinical outcomes or vaccine effectiveness, and to document and track changes that could alter the effectiveness of therapeutics. At present, almost 9 million genome sequences are now available via the GISAID Initiative, permitting near real-time surveillance of the unfolding pandemic (Shu and McCauley 2017; Meredith et al. 2020).

SARS-CoV-2 showed relatively inconsequential genetic change until late 2020 (MacLean et al. 2021). Subsequently, later months of 2020 were characterised by the emergence, across the globe, of VOCs possessing mutations that altered virus phenotype in terms of transmissibility and antigenicity (Harvey et al. 2021). Concurrently, shifts in the immune profile of the human population likely represented a change in the selective environment evidenced by an increase in dN/dS ratios indicative at positive selection at codons across the genome and notable levels of convergence across the global phylogeny (Martin et al. 2021). The continuing emergence of SARS-CoV-2 variants exhibiting heightened transmissibility or antigenic novelty necessitates tools to detect, describe, and track those antigenic changes and make this information accessible to researchers, public health agencies, and drug and vaccine developers so that the information becomes actionable

Since the beginning of the pandemic, several bioinformatics tools have been developed to analyse and generate outputs that support actionable information (e.g. Pangolin lineages https:// cov-lineages.org/index.html; https://filogeneti.ca/covizu/; https:// outbreak.info; COVID-19 CG https://covidcg.org; https://coval. ccpem.ac.uk/; CoV-GLUE http://cov-glue.cvr.gla.ac.uk, https:// nextstrain.org; and https://covariants.org—last accessed date: 16 March 2022). Although these tools have been essential for data curation, analysis research, and public health impact (Hufsky et al. 2021), they have been mainly focusing on the epidemiological aspects of the pandemic, lacking the relevant information from the literature on the immunological effect of mutations.

This scientific need led us to create the COG-UK-Mutation Explorer (COG-UK-ME), a web resource that provides tracking of non-synonymous mutations in SARS-CoV-2 genome. COG-UK-ME is based on UK data, and it has been developed by the COVID-19 Genomics UK (COG-UK) consortium—created to deliver largescale and rapid whole-genome virus sequencing to local National Health Service centres and the UK government. COG-UK-ME relies on CLIMB-COVID, a data-centric bioinformatics environment for centralising UK SARS-CoV-2 sequences (Nicholls et al. 2021a). Here, we describe COG-UK-ME and its main functionality. COG-UK-ME currently has around 5,000 users per month, with approximately 30 per cent from the UK, 20 per cent from the USA, and the remainder from other international locations.

COG-UK-ME has three aims: first, to make available amino acid mutations in a user-friendly way, enabling data transparency; second, to report on amino acid variation present in SARS-CoV-2 sequences that have been shown to confer resistance against antibodies or disrupt T cell epitope binding. The third is to report on the emergence of new mutations that have the potential to reduce the effectiveness of some therapeutics that have been granted approval for use. Data accumulating over a time course can be analysed so that trends can be detected and tracked.

2. Data analysis

COG-UK-ME is a publicly accessible web resource that displays in-depth information and analyses of SARS-COV-2 virus genome

mutations and variants. Sequence information is deposited daily on the MRC CLIMB-COVID platform (Nicholls et al. 2021a), which has been generated by the COG-UK Consortium, Wellcome Sanger Institute, public health agencies, and other approved providers. Virus lineages are assigned by using a phylogenetic framework to identify those lineages that contribute most to active spread (Rambaut et al. 2020; O'Toole et al. 2021). Mutations for UK sequences are then analysed on the CLIMB platform and linked with curated data on antigenicity, therapeutics, and drug resistance. The prepared data files are then transferred from CLIMB to a web server and visualised.

2.1 Tracking changes in the mutation count

COG-UK-ME shows a browsable dataset of all the amino acid sequence variations in SARS-CoV-2 protein sequences. These are shown for all data, and in the recent past—over the last 28 days—in the UK and in the four UK nations (England, Scotland, Wales, and Northern Ireland) ('Mutation Counts' and 'Mutations by week' tabs). The 'VOCs and VUIs in the UK' tab shows through tables and visualisations the number of sequences of variants under investigation (VUI) and VOCs as designated by the UK Health Security Agency (formerly Public Health England) (https:// www.gov.uk/government/publications/covid-19-variants-genom ically-confirmed-case-numbers/variants-distribution-of-casesdata—last accessed date: 16 March 2022) (Fig. 1A). COG-UK-ME

also provides visualisations of the spike protein structure showing the position of the VOC-defining mutations (Fig. 1B). Data are also placed in their geographical context by showing the number of sequences and percentage of variants per region (Nomenclature of Territorial Units for Statistics—NUTS1) ('Geographical distribution' tab).

2.2 Spike profile tracking

In addition to tracking the frequency of individual substitutions across the genome and of lineages identified as VOCs or VUIs, changes in the frequency of combinations of spike amino acid substitutions are tracked. Each spike profile is defined as the combination of substitutions compared with the original genotype (Wuhan-Hu-1). Profiles may represent monophyletic lineages or they may have arisen convergently across the phylogeny. Changes in profile frequency over the latest 56-day period are considered. For currently circulating profiles (those sampled within the latest 7 days), a sortable and searchable table includes information on the pango lineage(s) for which the profile has been associated, the number of substitutions comprising the profile, and the count of sequences across the latest 56-day and 28-day periods. The average growth rate (plotted on the y-axis in Fig. 2A) is calculated as the mean percentage change in frequency between each 2-week period within the 56-day period. As growth rates are sensitive to potentially stochastic changes at very low frequencies, we also calculate a statistic that estimates recent expansion or contraction of each profile, calculated over the 56-day period (plotted on the y-axis in Fig. 2B). For each profile, i, the absolute value for this statistic, X_i , is calculated using the observed frequency, $O_{i,i}$, of each profile, i, in each of the most recent 2-week periods, j, according to

$$X_{i} = \sum \frac{\left(O_{i,j} - E_{i}\right)^{2}}{E_{i}}$$

where E_i is the frequency of profile i over the full 8-week period under consideration. Thus, the value calculated is influenced by both the rate of change in profile frequency and the overall frequencies of a given profile and is more robust to stochastic





Figure 1. (A) Frequency plot showing the number of SARS-CoV-2 sequences per week for VOCs Alpha, Delta, Delta-AY4.2, Omicron BA.1 and BA.2, and 'other' pre-VOC variants (see key) in the UK. The light grey box covering the two most recent weeks indicates a period in which sequence counts are low due to a lag (Figure S1). (B) Spike protein structure showing locations of Delta- and Omicron-specific spike mutations. Ectodomain of the spike homotrimer in open conformation with individual spike protein chains shown in different colours. On each monomer, highlighted spheres show the locations of amino acid substitutions, deletions (Δ), or insertions (ins) that distinguish the Omicron (BA.1) variant, relative to the original genotype (Wuhan-Hu-1). These are annotated on the monomer with an 'up' receptor-binding domain where they are highlighted in red on teal. The substitution D614C, which is shared by common descent by all lineage B.1 descendants is italicised. The visualisation is made using a complete spike model (Woo et al. 2020), which is in turn based upon a partial cryo-EM structure (RCSB Protein Data Bank (PDB) ID: 6VSB (Wrapp et al. 2020)).

differences in profile frequency that tend to occur at low frequencies.

This monitoring of spike profiles allows the detection of emerging, potentially advantageous, spikes that might not be detected by surveillance methods conditioned on mutations previously determined to be noteworthy through experimentation or other means. This simple approach is complementary to more sophisticated phylogenetic approaches for the estimation of lineage-specific growth rates. One advantage of this simple non-phylogenetic approach is that the convergent accumulation of a substitution or combination of substitutions on a particular background is identified. Such a scenario could arise when there is strong selective pressure on a genotype (e.g. the introduction of a therapeutic). For example, this approach would quickly alert to the growth of a profile such as Delta + E484K emerging convergently across the Delta phylogeny in response to within-host, immune-mediated selection, even if the instances of this profile are interspersed across the phylogeny. С



E Spike profiles detected in the UK during the last week

Show 20 \$ entries					Search:	
Profile	Amino acid substitutions	Lineage(s) 🍦	Sequences 56 days	Sequences 28 days	Average growth rate (%)	Expansion/ contraction
Omicron (BA.2)	28	BA.2, None	54567	48046	275	0.6332
Omicron (BA.1) +R346K	31	BA.1.1, None, BA.1	148029	76360	16.17	0.03949
Omicron (BA.2) +P1162L	29	BA.2, None	266	258	373.86	0.007625
Omicron (BA.2) +L5F	29	BA.2	291	269	346.12	0.004299
Omicron (BA.2) +Q493L	29	BA.2, None	141	139	64.29	0.003623

Figure 2. Spike profiles sampled within 7 days of the latest UK sequence are summarised. Each spike profile is a set of amino acid substitutions listed relative to the original genotype (Wuhan-Hu-1). Figure prepared with data compiled on 27 February 2022 with a most recent sequence date of 24 February 2022. A) Points represent spike profiles positioned by the number of sequences in the latest 28-day period and the average growth rate calculated over the latest 56-day period. Points are coloured by an expansion/contraction statistic that takes both the rate of change in frequency and the overall frequencies of a profile into account. The cursor is hovering to show information associated with BA.2 + P1162L. B) Points represent spike profiles positioned by the number of sequence of the expansion/contraction statistic used to colour points in **A**. Here, points are coloured to show profiles associated with Delta, Omicron (BA.1/BA.1.x), and Omicron (BA.2) variants. The cursor is again positioned to highlight the position of BA.2 + P1162L. The plot has been zoomed to focus on profiles with 28-day counts between 100 and 1,000. C) Searchable table sorted to show the four profiles in the UK with the highest values in the expansion/contraction column. Further columns show profile numbers in the latest 28- and 56-day periods and average growth rate.

2.3 Antigenic changes

The 'Antigenic changes' tab shows a table listing all mutations in the spike protein present in the UK sequence dataset that have individually been associated with some significant degree of weaker virus neutralisation by convalescent plasma, postvaccination sera, or SARS-CoV-2 spike-specific mAbs (referred to as 'Escape mutations' in Fig. 3). Alongside links to the associated literature for each substitution, a confidence score representing the weight of evidence associated with each substitution is shown: 'high', whenever the antigenic role of mutation is supported by multiple studies, including at least one that reports an effect observed with (post-infection serum) convalescent plasma; 'medium', if the antigenic role of the mutation is supported by multiple studies; and 'low', when the mutation is supported by a single study (Fig. 3). In the 'VOCs + Antigenicity' tab, COG-UK-ME reports the occurrence of additional amino acid substitutions or deletions linked to antigenic change within each VOC (Fig. 4). Relative proportions (expressed as percentages) of sequences carrying specific mutations can give information about the antigenic diversity within a VOC lineage.

2.4 T cell epitope mutations

Similar to the 'Antigenic changes' tab, the 'T cell epitope mutations' tab shows amino acid replacements in experimentally proven T cell epitopes both in spike and in other proteins, which have been described in the literature. Data are further filtered based on experimental studies just defining T cell epitopes ('Epitope studies') or those reporting on the impact of specific mutations on T cell recognition ('Reduced T cell recognition'). Also shown are predicted antigen presentation likelihood percentile rank values to the experimentally proposed HLA restriction element based on the NetMHCpan (CD8) and NetMHCIIpan (CD4) 4.1 algorithms (https://services.healthtech.dtu.dk/service.php? NetMHCpan-4.1 and https://services.healthtech.dtu.dk/service. php?NetMHCIIpan-4.0—last accessed date: 16 March 2022)




Figure 3. Amino acid substitutions in the spike protein identified in the UK dataset (referred to as 'Escape mutations') that have been associated with weaker neutralisation of the virus by convalescent or post-vaccination plasma/serum or spike-specific monoclonal antibodies (mAbs) or that have been observed to emerge upon exposure to either mAbs or plasma in laboratory experiments.

*High confidence (red) refers to an antigenic role supported by multiple studies, including at least one that reports an effect observed with (post-infection serum) convalescent plasma; 'medium' (orange), if the antigenic role is supported by multiple studies; and 'low' (yellow), when the mutation is supported by a single study. The boxes above the table enable filtering by multiple criteria.

(Reynisson et al. 2020) for both the wild-type and mutant peptide variants. Here, peptides with predicted percentile rank scores of less than 2.0 for CD8 and less than 5.0 for CD4 are likely HLA binders. Amino acid replacements in any epitope are visualised through logo plots, in which each letter represents an amino acid replacement present in a specific epitope, and its height represents residue frequency. The number below the sequence logo shows the position relative to the start position of the epitope.

2.5 Drug resistance

The 'Drug resistance' and 'Ronapreve' tabs show tables and visualisations for those mutations associated with the resistance of SARS-CoV-2 to antiviral treatments (e.g. Remdesivir) and therapeutic mAb cocktails that are currently used in clinical settings (e.g. Ronapreve, cocktail of *casirivimab* and *imdevimab*) (Beigel et al. 2020; Sidebottom and Gill 2021). The UpSet plot in the Ronapreve tab allows users to track amino acid substitutions known to affect either *casirivimab* or *imdevimab* mAbs and in combination (Fig. 5). Other therapeutics will be added in the future.

3. Concluding remarks

Bioinformatics resources such as COG-UK-ME play an important role by providing clear and accessible information to those who are tackling the pandemic, including through public health actions and the development of vaccines and therapeutics. COG-UK-ME is unique in presenting data from a densely sequenced population with an emphasis on publicly available data (bioproject accession PRJEB37886 and public alignments https://www.cogconsortium.uk/tools-analysis/publicdata-analysis-2/—last accessed date: 16 March 2022). COG-UK-ME also brings together curated literature on the impact of mutations on various functional aspects of the virus. The COG-UK-ME interface allows users to track mutations that are a potential threat based on a phenotypic impact on virus biology or by conferring resistance to the human immune response, including that boosted by vaccines or antiviral drugs. Rapid analyses of VOCs, e.g. the accumulation of any mutation, can also be obtained from the COG-UK-ME interface. Of particular interest to researchers and for therapeutics are mutations that either have an antigenic role or affect T cell binding. These mutations are intensely monitored by researchers and Public Health Agencies to identify any new variant that could escape the immunity generated by vaccines. Timely identification of VOC/VUI samples can facilitate access to clinical specimens to isolate live virus and serum for further immunological evaluation.

Although amino acid sequence analyses are not sufficient to determine the functional effect of a single mutation on SARS-CoV-2 fitness when taken in isolation, COG-UK-ME strives to collate all the available literature on SARS-CoV-2 mutations and provides data to support experiments that investigate the change in phenotype that these mutations might confer on variants.

4. Methods

Throughout COG-UK-ME, Wuhan-Hu-1 (NCBI RefSeq NC_045512) is used as the reference sequence for nucleotide coordinates, codon numbering within viral proteins, and wild-type amino acid assignments. Sequences are regularly uploaded onto the MRC-CLIMB platform. Sequences with quality issues are excluded. Amino acid replacements and in-frame indels in each sequence are identified (Nicholls et al. 2021a).

Source code is available at https://github.com/wrightdw/COG-UK-ME (last accessed date: 16 March 2022).




Figure 4. Heatmap showing the frequency of spike amino acid substitutions and a deletion with a potential or confirmed antigenic role on top of BA.2 through time. The labelled structural domains are indicated on the left side: SP, signal peptide; NTD, N-terminal domain; RBD, receptor-binding domain; RBM, receptor-binding motif; S2, subunit; FP, fusion peptide. Residues are also coloured according to the class of antibody that binds to an epitope. RBD antibody Classes 1–4 (Barnes et al. 2020) are depicted by colours: green (Class 1: ACE2 blocking, bind open RBD only), yellow (Class 2: ACE2 blocking, bind open, and closed RBD), blue (Class 3: non-ACE2 blocking, bind open, and closed RBD), or yellow (Class 4: non-ACE2 blocking, bind open RBD only). Residues described in an NTD epitope (Chi et al. 2020) are coloured in magenta (Class 5). Each residue is also classified as having evidence for mutations either affecting neutralisation by mAbs (Baum et al. 2020; Li et al. 2020; Weisblum et al. 2020; Li u et al. 2021) or serum from previously infected individuals (convalescent plasma) (Li et al. 2020; Weisblum et al. 2020; Weisblum et al. 2020; Li u et al. 2021) or plasma (Weisblum et al. 2020) and emerging upon exposure to mAbs (Baum et al. 2020; Weisblum et al. 2020; Li u et al. 2021) or plasma

4.1 Data preparation

Sequence metadata files are processed on the CLIMB-COVID platform (Nicholls et al. 2021a) using the R statistical programming language (Team 2021) and the Tidyverse collection of R packages (Wickham et al. 2019). Non-UK sequences are filtered out. Amino acid replacements and reference amino acids are counted for all times and for a 28-day period up to and including the latest sequence date for the UK and the four UK nations. Counts are linked with data on antigenic changes, data on therapeutics, epitope data and predicted epitope binding percentile




Figure 5. UpSet plot showing the counts of mutations affecting Ronapreve constituent mAbs that have occurred individually and in combinations (Lex et al. 2014). Occurrence is shown in the full UK SARS-CoV-2 genome sequence dataset (A) and in a dataset compiled of sequences in the latest 28-day period (B). Spike amino acid substitutions known to affect either casirivimab or imdevimab mAbs were considered. The upper histogram shows the number of sequences per mutation (dots) or combination of mutations (lines), and the bottom left histogram presents the number of sequences with each specific substitution. Rows are coloured according to the mAb to which the greatest fold decrease in binding was recorded (blue = casirivimab, orange = imdevimab), with a lighter shade indicating a fold decrease of less than 100 and darker shade indicating 100 or greater.

rank values. Counts of all amino acids across all positions in the spike protein are prepared for the visualisation of sequence logos.

PANGO lineage name aliases are resolved to the full lineage names using the current designations at https://github.com/covlineages/pango-designation (last accessed date: 16 March 2022). VOC and VUI lineages are counted by day and by week for the UK and the four UK nations, counting AY.x sub-lineages within the Delta VOC hierarchically. VOC lineages are also counted by week and by geographic region according to the 12 Nomenclature of Territorial Units for Statistics first-level regions of the UK (NUTS1). Antigenic amino acid replacements and deletions in the spike protein are counted for VOC lineages, excluding lineage defining replacements, as defined by the UK Health Security Agency at https://github.com/phe-genomics/variant_definitions (last accessed date: 16 March 2022). Following data preparation, the resultant data files are transferred from CLIMB to a web server for visualisation.

4.2 Literature search

We searched PubMed, LitCovid, BioRxiv, and MedRxiv using the search term 'SARS-CoV-2' combined with 'mAbs', 'monoclonal', 'convalescent', 'neutralisation/neutralization', 'epitope', and 'antibody' for studies published from January 2020 to July 2021 and manually searched the references of select articles for additional relevant articles (Figure S2). We also searched BioRxiv, and MedRxiv using combinations of the search terms: 'COVID19', 'COVID-19', 'SARS-CoV-2', 'remdesivir', 'favipiravir', 'molnupiravir', 'nirmatrelvir', 'ritonavir', 'paxlovid', 'antiviral', 'binding', 'efficacy', 'effective', 'resistance', 'resistant', 'sensitivity', 'inhibit', 'evasion', 'mutation', and 'variant'. Results reporting on SARS-CoV-2 mutations that cause resistance to antiviral drugs were recorded and published on the dashboard. This included many different types of assays and studies: neutralisation assays, receptor binding assays, clinical efficacy studies, transcriptional inhibition assays, and in silico indications of resistance. Antiviral drugs are included in the review if they are clinically approved somewhere in the world or are in Stage 3 clinical trials. This search is repeated each week, allowing the timely updating of the dashboard when new research arises.

4.3 Data visualisation

The Shiny framework is used to create the COG-UK-ME web application, hosted in the Shiny Server environment (Chang et al. 2021). In order to maximise performance across multiple concurrent users, most values are pre-computed in the data preparation process on CLIMB, with the web application focussing on data visualisation.

The bar charts for VOC lineages and mutations, the geographical maps of VOC lineages, and the scatter plot of spike profiles are generated using ggplot2, with interactive features added using Plotly (2015). The heatmap of antigenic changes in the spike protein is generated using the *ComplexHeatmap* package (Gu et al. 2016), antigenic replacements, and structural domain classifications. Amino acid replacements in epitopes are visualised as sequence logos using the ggseqlogo package (Wagih 2017). UpSet plots for mutations affecting Ronapreve are generated using the *UpsetR* package (Lex et al. 2014; Conway et al. 2017). The web application user interface is created using the shinydashboard (Chang and Ribeiro 2021), shinydashboardPlus (Granjon 2021), shinyWidgets (Perrier et al. 2021), and shinyjs packages (Attali 2020).

For the visualisations of the VOC spike mutations on the structure, the file 6vsb_1_1_1.pdb containing a complete model of the full-length glycosylated spike homotrimer in open conformation with one monomer having the receptor-binding domain in the 'up' position was obtained from the CHARMM-GUI Archive (Woo et al. 2020; CHARMM-GUI Archive, 2021). This model is itself generated based upon a partial spike cryo-EM structure (PDB ID: 6VSB (Wrapp et al. 2020)). For visualisation, the model was trimmed to the ectodomain (Residues 14–1164) and the signal peptide (Residues 1–13) and glycans were removed. Figures were prepared using PyMol (Schrödinger-LLC 2010).

Supplementary data

Supplementary data is available at Virus Evolution online.

Acknowledgements

COG-UK-ME is enabled by data from COG-UK and MRC-CLIMB. All UK data are available in GISAID, and we thank all sequence generators for rapid data-sharing. We also acknowledge Omar Wagih for his support with his ggseqlogo sequence logo package used for visualising mutations in epitopes.

Funding

COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) (MC_PC_19027), and Genome Research Limited, operating as the Wellcome Sanger Institute. W.T.H. and T.P.P. are supported by the G2P-UK National Virology Consortium (MR/W005611/1) and W.T.H. by the MRC (MR/R024758/1). D.L.R., D.W., and J.H. are funded by the MRC (MC_UU_12014/12) and D.L.R. by the Wellcome Trust (220977/Z/20/Z).

Conflict of interest: None declared.

References

- Andreano, E. et al. (2021) 'SARS-CoV-2 Escape from a Highly Neutralizing COVID-19 Convalescent Plasma', Proceedings of the National Academy of Sciences, 118: e2103154118.
- Attali, D. (2020), Shinyjs: Easily Improve the User Experience of Your Shiny Apps in Seconds <<u>https://CRAN.R-project.org/package=shinyjs></u> accessed 16 Mar 2022.
- Barnes, C. O. et al. (2020) 'SARS-CoV-2 Neutralizing Antibody Structures Inform Therapeutic Strategies', Nature, 588: 682–7.
- Baum, A. et al. (2020) 'Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen with Individual Antibodies', Science, 369: 1014–8.
- Beigel, J. H. et al. (2020) 'Remdesivir for the Treatment of Covid-19 Final Report', New England Journal of Medicine, 383: 1813–26.
- Chang, W. et al. (2021), Shiny: Web Application Framework for R <<u>https://CRAN.R-project.org/package=shiny</u>> accessed 16 Mar 2022.
- Chang, W., and Ribeiro, B. B. (2021), Shinydashboard: Create Dashboards with 'Shiny' https://CRAN.R-project.org/package=shinydashboard> accessed 16 Mar 2022.
- CHARMM-GUI Archive. (2021), COVID-19 Proteins Library https://charmm-gui.org/?doc=archive&lib=covid19%202021 accessed 16 Mar 2022.
- Chi, X. et al. (2020) 'A Neutralizing Human Antibody Binds to the Nterminal Domain of the Spike Protein of SARS-CoV-2', *Science (New York*, N.Y.), 369: 650–5.
- Conway, J. R. et al. (2017) 'UpSetR: An R Package for the Visualization of Intersecting Sets and Their Properties', *Bioinformatics*, 33: 2938–40.
- Duchene, S. et al. (2020) 'Temporal Signal and the Phylodynamic Threshold of SARS-CoV-2', Virus Evolution, 6: veaa061.
- Granjon, D. (2021). 'shinydashboardPlus: Add More "AdminLTE2" Components to "shinydashboard".
- Greaney, A. J. et al. (2021) 'Comprehensive Mapping of Mutations in the SARS-CoV-2 Receptor-binding Domain that Affect Recognition by Polyclonal Human Plasma Antibodies', *Cell Host & Microbe*, 29: 463–76.e466.
- Gu, Z. et al. (2016) 'Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data', *Bioinformatics*, 32: 2847–9.
- Harvey, W. T. et al. (2021) 'SARS-CoV-2 Variants, Spike Mutations and Immune Escape', Nature Reviews. Microbiology, 19: 409–24.
- Houldcroft, C. J. et al. (2017) 'Clinical and Biological Insights from Viral Genome Sequencing', *Nature Reviews. Microbiology*, 15: 183–92.

- Hu, B. et al. (2021) 'Characteristics of SARS-CoV-2 and COVID-19', Nature Reviews. Microbiology, 19: 141–54.
- Hufsky, F. et al. (2021) 'Computational Strategies to Combat COVID-19: Useful Tools to Accelerate SARS-CoV-2 and Coronavirus Research', Briefings in Bioinformatics, 22: 642–63.
- Lex, A. et al. (2014) 'UpSet: Visualization of Intersecting Sets', IEEE Transactions on Visualization and Computer Graphics, 20: 1983–92.
- Li, Q. et al. (2020) 'The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity', *Cell*, 182: 1284–94.e1289.
- Liu, Z. et al. (2021) 'Identification of SARS-CoV-2 Spike Mutations that Attenuate Monoclonal and Serum Antibody Neutralization', Cell Host & Microbe, 29: 477–88.e474.
- MacLean, O. A. et al. (2021) 'Natural Selection in the Evolution of SARS-CoV-2 in Bats Created a Generalist Virus and Highly Capable Human Pathogen', PLoS Biology, 19: e3001115.
- Martin, D. P. et al. (2021) 'The Emergence and Ongoing Convergent Evolution of the SARS-CoV-2 N501Y Lineages', Cell, 184: 5189–200.e5187.
- Meredith, L. W. et al. (2020) 'Rapid Implementation of SARS-CoV-2 Sequencing to Investigate Cases of Health-care Associated COVID-19: A Prospective Genomic Surveillance Study', *The Lancet Infectious Diseases*, 20: 1263–72.
- Nicholls, S. M. et al. (2021) 'CLIMB-COVID: Continuous Integration Supporting Decentralised Sequencing for SARS-CoV-2 Genomic Surveillance', *Genome Biology*, 22: 196.
- O'Toole, Á. et al. (2021) 'Assignment of Epidemiological Lineages in an Emerging Pandemic Using the Pangolin Tool', Virus Evolution, 7: veab064.
- Perrier, V. et al. (2021). 'shinyWidgets: Custom Inputs Widgets for Shiny'.
- Plotly Technologies Inc. (2015), Collaborative Data Science https://plot.ly-accessed-16-Mar.2022.
- Rambaut, A. et al. (2020) 'A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology', Nature Microbiology, 5: 1403–7.
- Reynisson, B. et al. (2020) 'NetMHCpan-4.1 And NetMHCIIpan-4.0: Improved Predictions of MHC Antigen Presentation by Concurrent Motif Deconvolution and Integration of MS MHC Eluted Ligand Data', Nucleic Acids Research, 48: W449–54.
- Robson, F. et al. (2020) 'Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting', *Molecular Cell*, 79: 710–27.
- Schrödinger-LLC (2010) The PyMOL Molecular Graphics System https://www.pymol.org/> accessed 16 Mar 2022.
- Shu, Y., and McCauley, J. (2017) 'GISAID: Global Initiative on Sharing All Influenza Data - from Vision to Reality', Euro Surveillance : Bulletin European Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 22: 30494.
- Sidebottom, D. B., and Gill, D. (2021) 'Ronapreve for Prophylaxis and Treatment of Covid-19', BMJ, 374: n2136.
- Team, R. C. (2021) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria https://www.R-project.org/> accessed 16 Mar 2022.
- Wagih, O. (2017) 'Ggseqlogo: A Versatile R Package for Drawing Sequence Logos', Bioinformatics, 33: 3645–7.
- Wang, Z. et al. (2021) 'mRNA Vaccine-elicited Antibodies to SARS-CoV-2 and Circulating Variants', Nature, 592: 616–22.
- Weisblum, Y. et al. (2020) 'Escape from Neutralizing Antibodies by SARS-CoV-2 Spike Protein Variants', *eLife*, 9: e61312.

- Wickham, H. et al. (2019) 'Welcome to the Tidyverse', Journal of Open Source Software, 4: 1686.
- Woo, H. et al. (2020) 'Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane', *The Journal* of Physical Chemistry. B, 124: 7128–37.
- Wrapp, D. et al. (2020) 'Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation', *Science*, 367: 1260–3.

Appendix

The COVID-19 Genomics UK (COG-UK) consortium June 2021 V.1

Funding acquisition, Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation:

Dr Samuel C Robson ^{13, 84}

Funding acquisition, Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

Dr Thomas R Connor ^{11, 74} and Prof Nicholas J Loman ⁴³

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, Software and analysis tools, and Visualisation:

Dr Tanya Golubchik ⁵

Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation:

Dr Rocio T Martinez Nunez⁴⁶

Funding acquisition, Leadership and supervision, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

Dr David Bonsall ⁵

Funding acquisition, Leadership and supervision, Project administration, Sequencing and analysis, Software and analysis tools, and Visualisation:

Prof Andrew Rambaut ¹⁰⁴

Funding acquisition, Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

Dr Luke B Snell¹²

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, Software and analysis tools, and Visualisation:

Rich Livett ¹¹⁶

Funding acquisition, Leadership and supervision, Metadata curation, Project administration, and Samples and logistics: Dr Catherine Ludden ^{20,70}

Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and analysis: Dr Sally Corden ⁷⁴ and Dr Eleni Nastouli ^{96, 95, 30}

Funding acquisition, Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and analysis tools:

Dr Gaia Nebbia ¹²

Funding acquisition, Leadership and supervision, Project administration, Samples and logistics, and Sequencing and analysis:

Ian Johnston ¹¹⁶

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, and Sequencing and analysis:

Prof Katrina Lythgoe $^{\rm 5},$ Dr M. Estee Torok $^{19,\;20}$ and Prof Ian G Goodfellow $^{\rm 24}$

Leadership and supervision, Metadata curation, Project administration, Samples and logistics, and Visualisation:

Dr Jacqui A Prieto 97, 82 and Dr Kordo Saeed 97, 83

Leadership and supervision, Metadata curation, Project administration, Sequencing and analysis, and Software and analysis tools:

Dr David K Jackson ¹¹⁶

Leadership and supervision, Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation: Dr Catherine Houlihan ^{96, 94}

Leadership and supervision, Metadata curation, Sequencing and analysis, Software and analysis tools, and Visualisation: Dr Dan Frampton ^{94, 95}

Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools: Dr William L Hamilton 19 and Dr Adam A Witney 41

Funding acquisition, Samples and logistics, Sequencing and analysis, and Visualisation:

Dr Giselda Bucca ¹⁰¹

Funding acquisition, Leadership and supervision, Metadata curation, and Project administration:

Dr Cassie F Pope 40, 41

Funding acquisition, Leadership and supervision, Metadata curation, and Samples and logistics: Dr Catherine Moore ⁷⁴

Funding acquisition, Leadership and supervision, Metadata curation, and Sequencing and analysis:

Prof Emma C Thomson 53

Funding acquisition, Leadership and supervision, Project administration, and Samples and logistics: Dr Ewan M Harrison ^{116, 102}

Funding acquisition, Leadership and supervision, Sequencing and analysis, and Visualisation: Prof Colin P Smith ¹⁰¹

Leadership and supervision, Metadata curation, Project administration, and Sequencing and analysis:

Fiona Rogan 77

Leadership and supervision, Metadata curation, Project administration, and Samples and logistics:

Shaun M Beckwith ⁶, Abigail Murray ⁶, Dawn Singleton ⁶, Dr Kirstine Eastick ³⁷, Dr Liz A Sheridan ⁹⁸, Paul Randell ⁹⁹, Dr Leigh M Jackson ¹⁰⁵, Dr Cristina V Ariani ¹¹⁶ and Dr Sónia Gonçalves ¹¹⁶

Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and analysis:

Dr Derek J Fairley $^{3,\,77},$ Prof Matthew W Loose 18 and Joanne Watkins 74

Leadership and supervision, Metadata curation, Samples and logistics, and Visualisation:

Dr Samuel Moses ^{25, 106}

Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and analysis tools:

Dr Sam Nicholls $^{\rm 43},$ Dr Matthew Bull 74 and Dr Roberto Amato $^{\rm 116}$

Leadership and supervision, Project administration, Samples and logistics, and Sequencing and analysis:

Prof Darren L Smith ^{36, 65, 66}

Leadership and supervision, Sequencing and analysis, Software and analysis tools, and Visualisation:

Prof David M Aanensen $^{\rm 14,\,116}$ and Dr Jeffrey C Barrett $^{\rm 116}$

Metadata curation, Project administration, Samples and logistics, and Sequencing and analysis:

Dr Dinesh Aggarwal $^{20,\,116,\,70},$ Dr James G Shepherd $^{53},$ Dr Martin D Curran 71 and Dr Surendra Parmar 71

Metadata curation, Project administration, Sequencing and analysis, and Software and analysis tools:

Dr Matthew D Parker ¹⁰⁹

Metadata curation, Samples and logistics, Sequencing and analysis, and Software and analysis tools:

Dr Catryn Williams ⁷⁴

Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation:

Dr Sharon Glaysher ⁶⁸

Metadata curation, Sequencing and analysis, Software and analysis tools, and Visualisation:

Dr Anthony P Underwood ^{14, 116}, Dr Matthew Bashton ^{36, 65}, Dr Nicole Pacchiarini ⁷⁴, Dr Katie F Loveson ⁸⁴ and Matthew Byott ^{95, 96}

Project administration, Sequencing and analysis, Software and analysis tools, and Visualisation:

Dr Alessandro M Carabelli ²⁰

Funding acquisition, Leadership and supervision, and Metadata curation:

Dr Kate E Templeton ^{56, 104}

Funding acquisition, Leadership and supervision, and Project administration:

Dr Thushan I de Silva $^{\rm 109},$ Dr Dennis Wang $^{\rm 109},$ Dr Cordelia F Langford $^{\rm 116}$ and John Sillitoe $^{\rm 116}$

Funding acquisition, Leadership and supervision, and Samples and logistics:

Prof Rory N Gunson 55

Funding acquisition, Leadership and supervision, and Sequencing and analysis:

Dr Simon Cottrell ⁷⁴, Dr Justin O'Grady ^{75, 103} and Prof Dominic Kwiatkowski ^{116, 108}

Leadership and supervision, Metadata curation, and Project administration:

Dr Patrick J Lillie ³⁷

Leadership and supervision, Metadata curation, and Samples and logistics:

Dr Nicholas Cortes ³³, Dr Nathan Moore ³³, Dr Claire Thomas ³³, Phillipa J Burns ³⁷, Dr Tabitha W Mahungu ⁸⁰ and Steven Liggett ⁸⁶

Leadership and supervision, Metadata curation, and Sequencing and analysis:

Angela H Beckett ^{13, 81} and Prof Matthew TG Holden ⁷³

Leadership and supervision, Project administration, and Samples and logistics:

Dr Lisa J Levett $^{34},$ Dr Husam Osman $^{70,\,35}$ and Dr Mohammed O Hassan-Ibrahim 99

Leadership and supervision, Project administration, and Sequencing and analysis:

Dr David A Simpson 77

Leadership and supervision, Samples and logistics, and Sequencing and analysis:

Dr Meera Chand $^{72},$ Prof Ravi K Gupta $^{102},$ Prof Alistair C Darby 107 and Prof Steve Paterson 107

Leadership and supervision, Sequencing and analysis, and Software and analysis tools:

Prof Oliver G Pybus ²³, Dr Erik M Volz ³⁹, Prof Daniela de Angelis ⁵², Prof David L Robertson ⁵³, Dr Andrew J Page ⁷⁵ and Dr Inigo Martincorena ¹¹⁶

Leadership and supervision, Sequencing and analysis, and Visualisation:

Dr Louise Aigrain ¹¹⁶ and Dr Andrew R Bassett ¹¹⁶

Metadata curation, Project administration, and Samples and logistics:

Dr Nick Wong $^{50},$ Dr Yusri Taha $^{89},$ Michelle J Erkiert 99 and Dr Michael H Spencer Chapman $^{116,\ 102}$

Metadata curation, Project administration, and Sequencing and analysis:

Dr Rebecca Dewar $^{\rm 56}$ and Martin P McHugh $^{\rm 56,\,111}$

Metadata curation, Project administration, and Software and analysis tools:

Siddharth Mookerjee 38, 57

Metadata curation, Project administration, and Visualisation:

Stephen Aplin $^{97},$ Matthew Harvey $^{97},$ Thea Sass $^{97},$ Dr Helen Umpleby 97 and Helen Wheeler 97

Metadata curation, Samples and logistics, and Sequencing and analysis:

Dr James P McKenna ³, Dr Ben Warne ⁹, Joshua F Taylor ²², Yasmin Chaudhry ²⁴, Rhys Izuagbe ²⁴, Dr Aminu S Jahun ²⁴, Dr Gregory R Young ^{36,65}, Dr Claire McMurray ⁴³, Dr Clare M McCann ^{65,66}, Dr Andrew Nelson ^{65,66} and Scott Elliott ⁶⁸

Metadata curation, Samples and logistics, and Visualisation: Hannah Lowe $^{\rm 25}$

Metadata curation, Sequencing and analysis, and Software and analysis tools:

Dr Anna Price $^{11},\,$ Matthew R Crown $^{65},\,$ Dr Sara Rey $^{74},\,$ Dr Sunando Roy 96 and Dr Ben Temperton 105

Metadata curation, Sequencing and analysis, and Visualisation: Dr Sharif Shaaban ⁷³ and Dr Andrew R Hesketh ¹⁰¹

Project administration, Samples and logistics, and Sequencing and analysis:

Dr Kenneth G Laing $^{41},$ Dr Irene M Monahan 41 and Dr Judith Heaney $^{95,\;96,\;34}$

Project administration, Samples and logistics, and Visualisation:

Dr Emanuela Pelosi $^{97},$ Siona Silviera 97 and Dr Eleri Wilson-Davies 97

Samples and logistics, Software and analysis tools, and Visualisation:

Dr Helen Fryer ⁵

Sequencing and analysis, Software and analysis tools, and Visualization:

Dr Helen Adams ⁴, Dr Louis du Plessis ²³, Dr Rob Johnson ³⁹, Dr William T Harvey ^{53, 42}, Dr Joseph Hughes ⁵³, Dr Richard J Orton ⁵³, Dr Lewis G Spurgin ⁵⁹, Dr Yann Bourgeois ⁸¹, Dr Chris Ruis ¹⁰², Áine O'Toole ¹⁰⁴, Marina Gourtovaia ¹¹⁶ and Dr Theo Sanderson ¹¹⁶

Funding acquisition, and Leadership and supervision:

Dr Christophe Fraser ⁵, Dr Jonathan Edgeworth ¹², Prof Judith Breuer ^{96, 29}, Dr Stephen L Michell ¹⁰⁵ and Prof John A Todd ¹¹⁵

Funding acquisition, and Project administration:

Michaela John $^{
m 10}$ and Dr David Buck $^{
m 115}$

Leadership and supervision, and Metadata curation: Dr Kavitha Gajee ³⁷ and Dr Gemma L Kay ⁷⁵

Leadership and supervision, and Project administration: Prof Sharon J Peacock ^{20, 70} and David Heyburn ⁷⁴

Leadership and supervision, and Samples and logistics:

Katie Kitchman ³⁷, Prof Alan McNally ^{43, 93}, David T Pritchard ⁵⁰, Dr Samir Dervisevic ⁵⁸, Dr Peter Muir ⁷⁰, Dr Esther Robinson ^{70, 35}, Dr Barry B Vipond ⁷⁰, Newara A Ramadan ⁷⁸, Dr Christopher Jeanes ⁹⁰, Danni Weldon ¹¹⁶, Jana Catalan ¹¹⁸ and Neil Jones ¹¹⁸

Leadership and supervision, and Sequencing and analysis:

Dr Ana da Silva Filipe $^{53},$ Dr Chris Williams $^{74},$ Marc Fuchs $^{77},$ Dr Julia Miskelly $^{77},$ Dr Aaron R Jeffries $^{105},$ Karen Oliver 116 and Dr Naomi R Park 116

Metadata curation, and Samples and logistics:

Amy Ash¹, Cherian Koshy¹, Magdalena Barrow⁷, Dr Sarah L Buchan ⁷, Dr Anna Mantzouratou ⁷, Dr Gemma Clark ¹⁵, Dr Christopher W Holmes ¹⁶, Sharon Campbell ¹⁷, Thomas Davis ²¹, Ngee Keong Tan ²², Dr Julianne R Brown ²⁹, Dr Kathryn A Harris ^{29, 2}, Stephen P Kidd ³³, Dr Paul R Grant ³⁴, Dr Li Xu-McCrae ³⁵, Dr Alison Cox ^{38, 63}, Pinglawathee Madona ^{38, 63}, Dr Marcus Pond ^{38, 63}, Dr Paul A Randell ^{38, 63}, Karen T Withell ⁴⁸, Cheryl Williams ⁵¹, Dr Clive Graham ⁶⁰, Rebecca Denton-Smith ⁶², Emma Swindells ⁶², Robyn Turnbull ⁶², Dr Tim J Sloan ⁶⁷, Dr Andrew Bosworth ^{70, 35}, Stephanie Hutchings ⁷⁰, Hannah M Pymont ⁷⁰, Dr Anna Casey ⁷⁶, Dr Liz Ratcliffe ⁷⁶, Dr Christopher R Jones ^{79, 105}, Dr Bridget A Knight ^{79, 105}, Dr Tanzina Haque ⁸⁰, Dr Jennifer Hart ⁸⁰, Dr Dianne Irish-Tavares⁸⁰, Eric Witele⁸⁰, Craig Mower⁸⁶, Louisa K Watson ⁸⁶, Jennifer Collins ⁸⁹, Gary Eltringham ⁸⁹, Dorian Crudgington ⁹⁸, Ben Macklin⁹⁸, Prof Miren Iturriza-Gomara¹⁰⁷, Dr Anita O Lucaci ¹⁰⁷ and Dr Patrick C McClure ¹¹³

Metadata curation, and Sequencing and analysis:

Matthew Carlile ¹⁸, Dr Nadine Holmes ¹⁸, Dr Christopher Moore ¹⁸, Dr Nathaniel Storey ²⁹, Dr Stefan Rooke ⁷³, Dr Gonzalo Yebra ⁷³, Dr Noel Craine ⁷⁴, Malorie Perry ⁷⁴, Dr Nabil-Fareed Alikhan ⁷⁵, Dr Stephen Bridgett ⁷⁷, Kate F Cook ⁸⁴, Christopher Fearn ⁸⁴, Dr Salman Goudarzi ⁸⁴, Prof Ronan A Lyons ⁸⁸, Dr Thomas Williams ¹⁰⁴, Dr Sam T Haldenby ¹⁰⁷, Jillian Durham ¹¹⁶ and Dr Steven Leonard ¹¹⁶

Metadata curation, and Software and analysis tools:

Robert M Davies ¹¹⁶

Project administration, and Samples and logistics:

Dr Rahul Batra¹², Beth Blane²⁰, Dr Moira J Spyer^{30, 95, 96}, Perminder Smith^{32, 112}, Mehmet Yavus^{85, 109}, Dr Rachel J Williams⁹⁶, Dr Adhyana IK Mahanama⁹⁷, Dr Buddhini Samaraweera⁹⁷, Sophia T Girgis¹⁰², Samantha E Hansford¹⁰⁹, Dr Angie Green¹¹⁵, Dr Charlotte Beaver¹¹⁶, Katherine L Bellis^{116, 102}, Matthew J Dorman¹¹⁶, Sally Kay¹¹⁶, Liam Prestwood¹¹⁶ and Dr Shavanthi Rajatileka¹¹⁶

Project administration, and Sequencing and analysis:

Dr Joshua Quick 43

Project administration, and Software and analysis tools: Radoslaw Poplawski ⁴³

Samples and logistics, and Sequencing and analysis:

Dr Nicola Reynolds ⁸, Andrew Mack ¹¹, Dr Arthur Morriss ¹¹, Thomas Whalley ¹¹, Bindi Patel ¹², Dr Iliana Georgana ²⁴, Dr Myra Hosmillo²⁴, Malte L Pinckert²⁴, Dr Joanne Stockton⁴³, Dr John H Henderson ⁶⁵, Amy Hollis ⁶⁵, Dr William Stanley ⁶⁵, Dr Wen C Yew⁶⁵, Dr Richard Myers⁷², Dr Alicia Thornton⁷², Alexander Adams ⁷⁴, Tara Annett ⁷⁴, Dr Hibo Asad ⁷⁴, Alec Birchley ⁷⁴, Jason Coombes ⁷⁴, Johnathan M Evans ⁷⁴, Laia Fina ⁷⁴, Bree Gatica-Wilcox ⁷⁴, Lauren Gilbert ⁷⁴, Lee Graham ⁷⁴, Jessica Hey ⁷⁴, Ember Hilvers ⁷⁴, Sophie Jones ⁷⁴, Hannah Jones ⁷⁴, Sara Kumziene-Summerhayes ⁷⁴, Dr Caoimhe McKerr ⁷⁴, Jessica Powell ⁷⁴, Georgia Pugh ⁷⁴, Sarah Taylor ⁷⁴, Alexander J Trotter ⁷⁵, Charlotte A Williams ⁹⁶, Leanne M Kermack ¹⁰², Benjamin H Foulkes ¹⁰⁹, Marta Gallis ¹⁰⁹, Hailey R Hornsby ¹⁰⁹, Stavroula F Louka ¹⁰⁹, Dr Manoj Pohare¹⁰⁹, Paige Wolverson¹⁰⁹, Peijun Zhang¹⁰⁹, George MacIntvre-Cockett ¹¹⁵, Amy Trebes ¹¹⁵, Dr Robin J Moll ¹¹⁶, Lynne Ferguson¹¹⁷, Dr Emily J Goldstein¹¹⁷, Dr Alasdair Maclean¹¹⁷ and Dr Rachael Tomb ¹¹⁷

Samples and logistics, and Software and analysis tools: Dr Igor Starinskij ⁵³

Sequencing and analysis, and Software and analysis tools:

Laura Thomson ⁵, Joel Southgate ^{11,74}, Dr Moritz UG Kraemer ²³, Dr Jayna Raghwani ²³, Dr Alex E Zarebski ²³, Olivia Boyd ³⁹, Lily Geidelberg ³⁹, Dr Chris J Illingworth ⁵², Dr Chris Jackson ⁵², Dr David Pascall ⁵², Dr Sreenu Vattipally ⁵³, Timothy M Freeman ¹⁰⁹, Dr Sharon N Hsu ¹⁰⁹, Dr Benjamin B Lindsey ¹⁰⁹, Dr Keith James ¹¹⁶, Kevin Lewis ¹¹⁶, Gerry Tonkin-Hill ¹¹⁶ and Dr Jaime M Tovar-Corona ¹¹⁶

Sequencing and analysis, and Visualisation:

MacGregor Cox ²⁰

Software and analysis tools, and Visualisation:

Dr Khalil Abudahab ^{14, 116}, Mirko Menegazzo ¹⁴, Ben EW Taylor MEng ^{14, 116}, Dr Corin A Yeats ¹⁴, Afrida Mukaddas ⁵³, Derek W Wright ⁵³, Dr Leonardo de Oliveira Martins ⁷⁵, Dr Rachel Colquhoun ¹⁰⁴, Verity Hill ¹⁰⁴, Dr Ben Jackson ¹⁰⁴, Dr JT McCrone ¹⁰⁴, Dr Nathan Medd ¹⁰⁴, Dr Emily Scher ¹⁰⁴ and Jon-Paul Keatley ¹¹⁶

Leadership and supervision:

Dr Tanya Curran ³, Dr Sian Morgan ¹⁰, Prof Patrick Maxwell ²⁰, Prof Ken Smith ²⁰, Dr Sahar Eldirdiri ²¹, Anita Kenyon ²¹, Prof Alison H Holmes ^{38, 57}, Dr James R Price ^{38, 57}, Dr Tim Wyatt ⁶⁹, Dr Alison E Mather ⁷⁵, Dr Timofey Skvortsov ⁷⁷ and Prof John A Hartley ⁹⁶

Metadata curation:

Prof Martyn Guest ¹¹, Dr Christine Kitchen ¹¹, Dr Ian Merrick ¹¹, Robert Munn ¹¹, Dr Beatrice Bertolusso ³³, Dr Jessica Lynch ³³, Dr Gabrielle Vernet ³³, Stuart Kirk ³⁴, Dr Elizabeth Wastnedge ⁵⁶, Dr Rachael Stanley ⁵⁸, Giles Idle ⁶⁴, Dr Declan T Bradley ^{69,77}, Dr Jennifer Poyner ⁷⁹ and Matilde Mori ¹¹⁰

Project administration:

Owen Jones ¹¹, Victoria Wright ¹⁸, Ellena Brooks ²⁰, Carol M Churcher ²⁰, Mireille Fragakis ²⁰, Dr Katerina Galai ^{20, 70}, Dr Andrew Jermy ²⁰, Sarah Judges ²⁰, Georgina M McManus ²⁰, Kim S Smith ²⁰, Dr Elaine Westwick ²⁰, Dr Stephen W Attwood ²³, Dr Frances Bolt ^{38, 57}, Dr Alisha Davies ⁷⁴, Elen De Lacy ⁷⁴, Fatima Downing ⁷⁴, Sue Edwards ⁷⁴, Lizzie Meadows ⁷⁵, Sarah Jeremiah ⁹⁷, Dr Nikki Smith ¹⁰⁹ and Luke Foulser ¹¹⁶

Samples and logistics:

Dr Themoula Charalampous ^{12, 46}, Amita Patel ¹², Dr Louise Berry ¹⁵, Dr Tim Boswell ¹⁵, Dr Vicki M Fleming ¹⁵, Dr Hannah C Howson-Wells ¹⁵, Dr Amelia Joseph ¹⁵, Manjinder Khakh ¹⁵, Dr Michelle M Lister ¹⁵, Paul W Bird ¹⁶, Karlie Fallon ¹⁶, Thomas Helmer ¹⁶, Dr Claire L McMurray ¹⁶, Mina Odedra ¹⁶, Jessica Shaw¹⁶, Dr Julian W Tang¹⁶, Nicholas J Willford¹⁶, Victoria Blakey ¹⁷, Dr Veena Raviprakash ¹⁷, Nicola Sheriff ¹⁷, Lesley-Anne Williams ¹⁷, Theresa Feltwell ²⁰, Dr Luke Bedford ²⁶, Dr James S Cargill²⁷, Warwick Hughes²⁷, Dr Jonathan Moore²⁸, Susanne Stonehouse²⁸, Laura Atkinson²⁹, Jack CD Lee²⁹, Dr Divya Shah²⁹, Adela Alcolea-Medina ^{32, 112}, Natasha Ohemeng-Kumi ^{32, 112}, John Ramble ^{32, 112}, Jasveen Sehmi ^{32, 112}, Dr Rebecca Williams ³³, Wendy Chatterton ³⁴, Monika Pusok ³⁴, William Everson ³⁷, Anibolina Castigador ⁴⁴, Emily Macnaughton ⁴⁴, Dr Kate El Bouzidi ⁴⁵, Dr Temi Lampejo⁴⁵, Dr Malur Sudhanva⁴⁵, Cassie Breen⁴⁷, Dr Graciela Sluga ⁴⁸, Dr Shazaad SY Ahmad ^{49,70}, Dr Ryan P George ⁴⁹, Dr Nicholas W Machin^{49,70}, Debbie Binns⁵⁰, Victoria James⁵⁰, Dr Rachel Blacow ⁵⁵, Dr Lindsay Coupland ⁵⁸, Dr Louise Smith ⁵⁹, Dr Edward Barton⁶⁰, Debra Padgett⁶⁰, Garren Scott⁶⁰, Dr Aidan Cross ⁶¹, Dr Mariyam Mirfenderesky ⁶¹, Jane Greenaway ⁶², Kevin Cole ⁶⁴, Phillip Clarke⁶⁷, Nichola Duckworth⁶⁷, Sarah Walsh⁶⁷, Kelly Bicknell ⁶⁸, Robert Impey ⁶⁸, Dr Sarah Wyllie ⁶⁸, Richard Hopes ⁷⁰, Dr Chloe Bishop 72, Dr Vicki Chalker 72, Dr Ian Harrison 72, Laura Gifford ⁷⁴, Dr Zoltan Molnar ⁷⁷, Dr Cressida Auckland ⁷⁹, Dr Cariad Evans^{85, 109}, Dr Kate Johnson^{85, 109}, Dr David G Partridge^{85, 109}, Dr Mohammad Raza^{85, 109}, Paul Baker⁸⁶, Prof Stephen Bonner⁸⁶, Sarah Essex ⁸⁶, Leanne J Murray ⁸⁶, Andrew I Lawton ⁸⁷, Dr Shirelle Burton-Fanning⁸⁹, Dr Brendan AI Payne⁸⁹, Dr Sheila Waugh⁸⁹, Andrea N Gomes ⁹¹, Maimuna Kimuli ⁹¹, Darren R Murray ⁹¹, Paula Ashfield ⁹², Dr Donald Dobie ⁹², Dr Fiona Ashford ⁹³, Dr Angus Best ⁹³, Dr Liam Crawford ⁹³, Dr Nicola Cumley ⁹³, Dr Megan Mayhew ⁹³, Dr Oliver Megram ⁹³, Dr Jeremy Mirza ⁹³, Dr Emma Moles-Garcia ⁹³, Dr Benita Percival ⁹³, Megan Driscoll ⁹⁶, Leah Ensell ⁹⁶, Dr Helen L Lowe ⁹⁶, Laurentiu Maftei ⁹⁶, Matteo Mondani ⁹⁶, Nicola J Chaloner 99, Benjamin J Cogger 99, Lisa J Easton 99, Hannah Huckson ⁹⁹, Jonathan Lewis ⁹⁹, Sarah Lowdon ⁹⁹, Cassandra S Malone ⁹⁹, Florence Munemo ⁹⁹, Manasa Mutingwende ⁹⁹, Roberto Nicodemi ⁹⁹, Olga Podplomyk ⁹⁹, Thomas Somassa ⁹⁹, Dr Andrew Beggs ¹⁰⁰, Dr Alex Richter ¹⁰⁰, Claire Cormie ¹⁰², Joana Dias ¹⁰², Sally Forrest ¹⁰², Dr Ellen E Higginson ¹⁰², Mailis Maes ¹⁰², Jamie Young ¹⁰², Dr Rose K Davidson ¹⁰³, Kathryn A Jackson ¹⁰⁷, Dr Lance Turtle ¹⁰⁷, Dr Alexander J Keeley ¹⁰⁹, Prof Jonathan Ball ¹¹³, Timothy Byaruhanga ¹¹³, Dr Joseph G Chappell ¹¹³, Jayasree Dey ¹¹³, Jack D Hill ¹¹³, Emily J Park ¹¹³, Arezou Fanaie ¹¹⁴, Rachel A Hilson ¹¹⁴, Geraldine Yaze $^{\rm 114}$ and Stephanie Lo $^{\rm 116}$

Sequencing and analysis:

Safiah Afifi ¹⁰, Robert Beer ¹⁰, Joshua Maksimovic ¹⁰, Kathryn McCluggage ¹⁰, Karla Spellman ¹⁰, Catherine Bresner ¹¹, William Fuller¹¹, Dr Angela Marchbank¹¹, Trudy Workman¹¹, Dr Ekaterina Shelest ^{13, 81}, Dr Johnny Debebe ¹⁸, Dr Fei Sang ¹⁸, Dr Marina Escalera Zamudio²³, Dr Sarah Francois²³, Bernardo Gutierrez ²³, Dr Tetyana I Vasylyeva ²³, Dr Flavia Flaviani ³¹, Dr Manon Ragonnet-Cronin ³⁹, Dr Katherine L Smollett ⁴², Alice Broos ⁵³, Daniel Mair ⁵³, Jenna Nichols ⁵³, Dr Kyriaki Nomikou ⁵³, Dr Lily Tong ⁵³, Ioulia Tsatsani ⁵³, Prof Sarah O'Brien ⁵⁴, Prof Steven Rushton $^{54},$ Dr Roy Sanderson $^{54},$ Dr Jon Perkins $^{55},$ Seb Cotton $^{56},$ Abbie Gallagher ⁵⁶, Dr Elias Allara ^{70, 102}, Clare Pearson ^{70, 102}, Dr David Bibby ⁷², Dr Gavin Dabrera ⁷², Dr Nicholas Ellaby ⁷², Dr Eileen Gallagher 72, Dr Jonathan Hubb 72, Dr Angie Lackenby 72, Dr David Lee ⁷², Nikos Manesis ⁷², Dr Tamyo Mbisa ⁷², Dr Steven Platt ⁷², Katherine A Twohig⁷², Dr Mari Morgan⁷⁴, Alp Aydin⁷⁵, David J Baker⁷⁵, Dr Ebenezer Foster-Nyarko⁷⁵, Dr Sophie J Prosolek⁷⁵, Steven Rudder ⁷⁵, Chris Baxter ⁷⁷, Sílvia F Carvalho ⁷⁷, Dr Deborah Lavin ⁷⁷, Dr Arun Mariappan⁷⁷, Dr Clara Radulescu⁷⁷, Dr Aditi Singh⁷⁷, Miao Tang 77, Helen Morcrette 79, Nadua Bayzid 96, Marius Cotic ⁹⁶, Dr Carlos E Balcazar ¹⁰⁴, Dr Michael D Gallagher ¹⁰⁴, Dr Daniel Maloney ¹⁰⁴, Thomas D Stanton ¹⁰⁴, Dr Kathleen A Williamson ¹⁰⁴, Dr Robin Manley ¹⁰⁵, Michelle L Michelsen ¹⁰⁵, Dr Christine M Sambles ¹⁰⁵, Dr David J Studholme ¹⁰⁵, Joanna Warwick-Dugdale ¹⁰⁵, Richard Eccles ¹⁰⁷, Matthew Gemmell ¹⁰⁷, Dr Richard Gregory ¹⁰⁷, Dr Margaret Hughes ¹⁰⁷, Charlotte Nelson ¹⁰⁷, Dr Lucille Rainbow ¹⁰⁷, Dr Edith E Vamos ¹⁰⁷, Hermione J Webster ¹⁰⁷, Dr Mark Whitehead ¹⁰⁷, Claudia Wierzbicki ¹⁰⁷, Dr Adrienn Angyal ¹⁰⁹, Dr Luke R Green $^{109},\,\mathrm{Dr}$ Max Whiteley $^{109},\,\mathrm{Emma}$ Betteridge $^{116},\,\mathrm{Dr}$ Iraad F Bronner ¹¹⁶, Ben W Farr ¹¹⁶, Scott Goodwin ¹¹⁶, Dr Stefanie V Lensing ¹¹⁶, Shane A McCarthy ^{116, 102}, Dr Michael A Quail ¹¹⁶, Diana Rajan¹¹⁶, Dr Nicholas M Redshaw¹¹⁶, Carol Scott¹¹⁶, Lesley Shirley ¹¹⁶ and Scott AJ Thurston ¹¹⁶

Software and analysis tools:

Dr Will Rowe ⁴³, Amy Gaskin ⁷⁴, Dr Thanh Le-Viet ⁷⁵, James Bonfield ¹¹⁶, Jennifier Liddle ¹¹⁶ and Andrew Whitwham ¹¹⁶

1 Barking, Havering and Redbridge University Hospitals NHS Trust, 2 Barts Health NHS Trust, 3 Belfast Health & Social Care Trust, 4 Betsi Cadwaladr University Health Board, 5 Big Data Institute, Nuffield Department of Medicine, University of Oxford, 6 Blackpool Teaching Hospitals NHS Foundation Trust, 7 Bournemouth University, 8 Cambridge Stem Cell Institute, University of Cambridge, 9 Cambridge University Hospitals NHS Foundation Trust, 10 Cardiff and Vale University Health Board, 11 Cardiff University, 12 Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, 13 Centre for Enzyme Innovation, University of Portsmouth, 14 Centre for Genomic Pathogen Surveillance, University of Oxford, 15 Clinical Microbiology Department, Queens Medical Centre, Nottingham University Hospitals NHS Trust, 16 Clinical Microbiology, University Hospitals of Leicester NHS Trust, 17 County Durham and Darlington NHS Foundation Trust, 18 Deep Seq, School of Life Sciences, Queens Medical Centre, University of Nottingham, 19 Department of Infectious Diseases and Microbiology, Cambridge University Hospitals NHS Foundation Trust, 20 Department of Medicine, University of Cambridge, 21 Department of Microbiology, Kettering General Hospital, 22 Department of Microbiology, South West London Pathology, 23 Department of Zoology, University of Oxford, 24 Division of Virology, Department of Pathology, University of Cambridge, 25 East Kent Hospitals University NHS

Foundation Trust, 26 East Suffolk and North Essex NHS Foundation Trust, 27 East Sussex Healthcare NHS Trust, 28 Gateshead Health NHS Foundation Trust, 29 Great Ormond Street Hospital for Children NHS Foundation Trust, 30 Great Ormond Street Institute of Child Health (GOS ICH), University College London (UCL), 31 Guy's and St. Thomas' Biomedical Research Centre, 32 Guy's and St. Thomas' NHS Foundation Trust, 33 Hampshire Hospitals NHS Foundation Trust, 34 Health Services Laboratories, 35 Heartlands Hospital, Birmingham, 36 Hub for Biotechnology in the Built Environment, Northumbria University, 37 Hull University Teaching Hospitals NHS Trust, 38 Imperial College Healthcare NHS Trust, 39 Imperial College London, 40 Infection Care Group, St George's University Hospitals NHS Foundation Trust, 41 Institute for Infection and Immunity, St George's University of London, 42 Institute of Biodiversity, Animal Health & Comparative Medicine, 43 Institute of Microbiology and Infection, University of Birmingham, 44 Isle of Wight NHS Trust, 45 King's College Hospital NHS Foundation Trust, 46 King's College London, 47 Liverpool Clinical Laboratories, 48 Maidstone and Tunbridge Wells NHS Trust, 49 Manchester University NHS Foundation Trust, 50 Microbiology Department, Buckinghamshire Healthcare NHS Trust, 51 Microbiology, Royal Oldham Hospital, 52 MRC Biostatistics Unit, University of Cambridge, 53 MRC-University of Glasgow Centre for Virus Research, 54 Newcastle University, 55 NHS Greater Glasgow and Clyde, 56 NHS Lothian, 57 NIHR Health Protection Research Unit in HCAI and AMR, Imperial College London, 58 Norfolk and Norwich University Hospitals NHS Foundation Trust, 59 Norfolk County Council, 60 North Cumbria Integrated Care NHS Foundation Trust, 61 North Middlesex University Hospital NHS Trust, 62 North Tees and Hartlepool NHS Foundation Trust, 63 North West London Pathology, 64 Northumbria Healthcare NHS Foundation Trust, 65 Northumbria University, 66 NU-OMICS, Northumbria University, 67 Path Links, Northern Lincolnshire and Goole NHS Foundation Trust, 68 Portsmouth Hospitals University NHS Trust, 69 Public Health Agency, Northern Ireland, 70 Public Health England, 71 Public Health England, Cambridge, 72 Public Health England, Colindale, 73 Public Health Scotland, 74 Public Health Wales, 75 Quadram Institute Bioscience, 76 Queen Elizabeth Hospital, Birmingham, 77 Queen's University Belfast, 78 Royal Brompton and Harefield Hospitals, 79 Royal Devon and Exeter NHS Foundation Trust, 80 Royal Free London NHS Foundation Trust, 81 School of Biological Sciences, University of Portsmouth, 82 School of Health Sciences, University of Southampton, 83 School of Medicine, University of Southampton, 84 School of Pharmacy & Biomedical Sciences, University of Portsmouth, 85 Sheffield Teaching Hospitals NHS Foundation Trust, 86 South Tees Hospitals NHS Foundation Trust, 87 Southwest Pathology Services, 88 Swansea University, 89 The Newcastle upon Tyne Hospitals NHS Foundation Trust, 90 The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, 91 The Royal Marsden NHS Foundation Trust, 92 The Royal Wolverhampton NHS Trust, 93 Turnkey Laboratory, University of Birmingham, 94 University College London Division of Infection and Immunity, 95 University College London Hospital Advanced Pathogen Diagnostics Unit, 96 University College London Hospitals NHS Foundation Trust, 97 University Hospital Southampton NHS Foundation Trust, 98 University Hospitals Dorset NHS Foundation Trust, 99 University Hospitals Sussex NHS Foundation Trust, 100 University of Birmingham, 101 University of Brighton, 102 University of Cambridge, 103 University of East Anglia, 104 University of Edinburgh, 105 University of Exeter, 106 University of Kent, 107 University of Liverpool, 108 University of

Oxford, **109** University of Sheffield, **110** University of Southampton, **111** University of St Andrews, **112** Viapath, Guy's and St Thomas' NHS Foundation Trust, and King's College Hospital NHS Foundation Trust, **113** Virology, School of Life Sciences, Queens Medical Centre, University of Nottingham, **114** Watford General

Hospital, **115** Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, **116** Wellcome Sanger Institute, **117** West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde, **118** Whittington Health NHS Trust